TECTA

Across TCGA pan-cancer cohorts, TECTA mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TECTA’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TECTA mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TECTA is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

HNSC, CCRCC, and LSCC are the cancer types where TECTA tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TECTA mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.034	<.001	12	view →
CCRCC	All	III,IV	+0.831	<.001	10	view →
LSCC	Female	All	+2.627	<.001	9	view →
COAD	Female	III,IV	−0.870	<.001	9	view →
PDAC	Female	II,III,IV	+1.659	<.001	8	view →
LUAD	Male	All	+0.482	.001	3	view →
OV	All	All	+1.092	.032	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TECTA–HNSC

Open the HNSC breakdown →